VRDN earnings analysis
What we found in VRDN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Viridian Therapeutics reported substantial financial losses in Q1 2026, with a revenue of only $6, a stark decline from prior periods, resulting in an EPS of -$0.90. The company highlighted the launch readiness for its therapy veligrotug, pending PDUFA approval scheduled for June 30, 2026. Management also noted a significant increase in SG&A expenses related to commercialization preparation.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Minimal Revenue Reported
- The company recorded revenues of $6, sharply down compared to $72 million in Q1 2025.
- Large Net Loss
- Viridian incurred a net loss of $104.9 million in Q1 2026, increased from a net loss of $86.9 million in Q1 2025.
- Cash Reserves Increase
- Total cash, cash equivalents and marketable securities stood at $762.2 million as of March 31, 2026.
- R&D Expenses Surge
- R&D expenses totaled $77.6 million, slightly higher than $76.8 million in Q1 2025.
- Increased SG&A Expenses
- SG&A expenses escalated to $38.7 million from $17.1 million year-over-year.
- Interest Income Up
- Other income, net was reported at $11.3 million, an increase from $7.0 million in Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Operational Viability Concerns
- The company reported an accumulated deficit of $1.444 billion as of March 31, 2026.
- Burn Rate
- Operating cash flow was $(119.7) million in Q1 2026, worse than $(92.7) million for the same period last year.
- Regulatory Uncertainty
- PDUFA for veligrotug is set for June 30, 2026, with uncertain outcomes affecting future sales.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.9
What they said about what is next.
The company did not provide specific numeric guidance in the filing, focusing on upcoming regulatory timelines.
The filing reads worse than the one before it.
What came before.
- 10-K · February 26, 2026
- Viridian positions itself as a clinical‑stage biopharma focused on best‑in‑class antibody therapeutics for thyroid eye disease (TED) and autoimmune disorders, advancing veligrotug (IV) and elegrobart (SC) as lead IGF‑1R…
- 10-Q · May 6, 2025
- Viridian reported collaboration revenue of $72 for Q1 2025 and a net loss of $86,912, driven by a $76,835 R&D spend. The company holds approximately $636.6 million of cash, cash equivalents and short-term investments…
- 10-K · March 3, 2025
- Viridian’s 10-K emphasizes a clinical-stage, fast-follower biologics strategy focused on thyroid eye disease (TED) and engineered FcRn inhibitors, with pivotal phase 3 successes for veligrotug (THRIVE and THRIVE-2) and…
- 10-Q · November 12, 2024
- Viridian reported collaboration revenue of $86,000 for Q3 2024 and a GAAP net loss of $76,689,000 (EPS $(1.15)) for the three months ended September 30, 2024. Revenue rose modestly versus the prior-year quarter…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing VRDN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever